Table 6.
Summary of common (occurring in ≥ 10% of participants) treatment-emergent adverse events in a phase 3 study of burosumab in adults with X-linked hypophosphatemia [13]
| Treatment-emergent AEs, n (5) | Placebo Q4W (n = 66) | Burosumab Q4W (n = 68) |
|---|---|---|
| Back pain | 6 (9) | 10 (15) |
| Nasopharyngitis | 6 (9) | 9 (13) |
| Tooth abscess | 5 (8) | 9 (13) |
| Headache | 5 (8) | 8 (12) |
| Nausea | 6 (9) | 7 (10) |
| Dizziness | 4 (6) | 7 (10) |
| Arthralgia | 16 (24) | 6 (9) |
| Pain in extremity | 10 (15) | 5 (8) |
| Oropharyngeal pain | 7 (11) | 1 (2) |
Abbreviations: AE, adverse events; Q4W, every 4 weeks.